Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807425 | 0.81 | OPRL1 (0.47) | OPRL1RORC | |
| SCHEMBL11949323 | 0.81 | RORC (0.55) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL31252999 | 0.79 | RORC (0.51) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL31387399 | 0.79 | OPRL1 (0.47) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL25356792 | 0.79 | OPRL1 (0.47) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL25359159 | 0.79 | OPRL1 (0.47) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL25357972 | 0.79 | OPRL1 (0.47) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL18579655 | 0.79 | OPRL1 (0.45) | OPRL1RORCSIGMAR1TAAR1 | |
| SCHEMBL31243799 | 0.78 | OPRL1 (0.50) | OPRL1RORCSIGMAR1 | |
| SCHEMBL20487669 | 0.77 | OPRL1 (0.39) | OPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501704-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2501703-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | OPRL1 4/4885RORC 932/4885SIGMAR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.